Medfinder
Back to blog

Updated: January 26, 2026

How Does Nexlizet Work? Mechanism of Action Explained in Plain English

Author

Peter Daggett

Peter Daggett

Body silhouette with glowing pathways showing how cholesterol medication works

Nexlizet lowers cholesterol in two different ways. Here's a plain-English breakdown of how bempedoic acid and ezetimibe each work — and why the combination matters.

One of the most common questions patients have about Nexlizet is: how exactly does it work? The short answer is that Nexlizet uses two medications working through two completely different pathways to lower LDL cholesterol — one targets cholesterol production in your liver, and the other targets cholesterol absorption in your gut. Together, they can lower LDL by approximately 35-38%. Here's the full picture in plain language.

The Two Ingredients and What They Each Do

Nexlizet contains two separate medicines:

Bempedoic acid (180 mg): Reduces how much cholesterol your liver makes

Ezetimibe (10 mg): Reduces how much cholesterol your gut absorbs from food and bile

These two mechanisms are complementary — they attack LDL from two angles simultaneously. This is why the combination is more effective than either drug alone.

How Bempedoic Acid Works: Stopping Cholesterol at the Source

Your liver is the main source of cholesterol in your body — about 80% of the cholesterol in your blood is produced by the liver, not from the food you eat. Your liver uses a multi-step assembly line to build cholesterol.

If you've heard of statins, you know they block a key enzyme in this process called HMG-CoA reductase (the "statin target"). Bempedoic acid works at a different step in the same assembly line — it blocks an enzyme called ATP-citrate lyase (ACL), which is two steps upstream of where statins work.

Think of it like stopping a factory earlier in the production line. By blocking ACL, bempedoic acid reduces the amount of acetyl-CoA (a building block) available to make cholesterol, ultimately reducing LDL production in the liver.

Why Bempedoic Acid Doesn't Cause Muscle Pain Like Statins

Here's the important part for statin-intolerant patients: bempedoic acid is what's called a prodrug. After you swallow it, it gets converted into its active form (ESP15228) specifically in the liver — but not in skeletal muscle. This happens because the enzyme needed to activate the drug (called ACSVL1) is present in the liver but not in skeletal muscle.

This is why Nexlizet causes far fewer muscle-related side effects than high-dose statins. Statins work inside muscle cells too, which is why some patients experience myalgia (muscle pain) or even rhabdomyolysis (muscle breakdown). Bempedoic acid stays out of muscles, targeting cholesterol production only in the liver.

How Ezetimibe Works: Blocking Cholesterol at the Door

Ezetimibe works in your small intestine, not your liver. When you eat food, your gut absorbs cholesterol from both dietary sources (what you eat) and bile (cholesterol-rich fluid your liver secretes to help digest fats). Ezetimibe blocks a protein called NPC1L1 (Niemann-Pick C1-Like 1) that acts as a "doorway" on the surface of intestinal cells, allowing cholesterol to pass through the gut wall into the bloodstream.

By blocking NPC1L1, ezetimibe prevents cholesterol from crossing that doorway. Less cholesterol enters the bloodstream from the gut, so the liver compensates by pulling more LDL out of the blood — lowering your LDL cholesterol level. Ezetimibe alone reduces LDL by about 15-20%.

How the Two Work Together to Achieve Greater LDL Reduction

Here's the synergy in simple terms:

Bempedoic acid tells the liver: "Make less cholesterol"

Ezetimibe tells the gut: "Absorb less cholesterol from food and bile"

The liver, getting less cholesterol from both production AND absorption, responds by pulling more LDL out of the bloodstream — further lowering LDL levels

The result: clinical trials show Nexlizet reduces LDL by approximately 36-38% versus placebo, compared to ~17-21% for bempedoic acid alone and ~15-20% for ezetimibe alone. The combination delivers more than the sum of its parts because both pathways reinforce each other.

Does Nexlizet Also Reduce Inflammation?

Yes. The bempedoic acid component of Nexlizet also reduces hsCRP (high-sensitivity C-reactive protein), a marker of inflammation in the body. In clinical trials, bempedoic acid reduced hsCRP by 22-35% compared to placebo. Inflammation plays a role in the development of atherosclerosis (plaque buildup in arteries), so this anti-inflammatory effect may contribute to Nexlizet's cardiovascular protective benefits beyond LDL reduction alone.

Now that you understand how Nexlizet works, you might also want to know what Nexlizet is used for and how to take it.

If you're struggling to find Nexlizet at a pharmacy near you, medfinder can help you locate which pharmacies have it in stock.

Frequently Asked Questions

Nexlizet uses two mechanisms simultaneously. Bempedoic acid inhibits ATP-citrate lyase (ACL) in the liver, reducing cholesterol production. Ezetimibe blocks the NPC1L1 transporter in the small intestine, reducing cholesterol absorption from food and bile. Together, they lower LDL cholesterol by approximately 35-38%.

Statins block HMG-CoA reductase in the cholesterol production pathway. Bempedoic acid blocks ACL, which is two steps upstream of statins in the same pathway. Importantly, bempedoic acid is only activated in the liver — not in skeletal muscle — which means it causes fewer muscle side effects than statins. Nexlizet is typically used when patients cannot tolerate statins or need additional LDL reduction beyond what a statin alone provides.

Bempedoic acid is a prodrug that must be converted into its active form by an enzyme called ACSVL1. This enzyme is present in the liver but not in skeletal muscle. As a result, bempedoic acid is activated only in the liver and doesn't affect muscle cells — which is why muscle pain and weakness are rare with Nexlizet compared to statins.

Yes. The bempedoic acid component of Nexlizet reduces hsCRP (high-sensitivity C-reactive protein) — a marker of systemic inflammation — by 22-35% compared to placebo in clinical trials. Since inflammation contributes to atherosclerosis and cardiovascular risk, this anti-inflammatory effect is an added benefit beyond LDL reduction.

Nexlizet begins lowering LDL within the first 2-4 weeks of treatment, with most of the effect established by week 12. Your doctor will typically check your lipid levels 8-12 weeks after starting to assess response. The effect continues as long as you take the medication; LDL returns toward previous levels once you stop.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Nexlizet also looked for:

36,651 have already found their meds with Medfinder.

Start your search today.

36K+
5-star ratingTrusted by 36,651 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?